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https://doi.org/10.101Despite recent identification of several prognostic markers, there is still a need for new
prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia
(CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic)
markers measured pretreatment and to search for new proteomic markers that might
be related to treatment response in CLL. To this end, baseline serum samples of 51
CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic
markers, using Olink technology. Median event-free survival (EFS) was 23 months
(range: 1.25−60.9). Patients with high levels of sCD23 (>11.27, p = 0.026), sCD27
(>11.03, p = 0.04), SPINT1 (>1.6, p = 0.001), and LY9 (>8.22, p = 0.0003) had a shorter
EFS than those with marker levels below the median. The effect of sCD23 on EFS dif-
fered between immunoglobulin heavy chain variable gene-mutated and unmutated
patients, with the shortest EFS for unmutated CLL patients with sCD23 levels above
the median. Taken together, our results validate the prognostic impact of sCD23 andshare senior authorship. FSH, AWL, and MDL
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56 F. Saberi Hosnijeh et al. / Experimental Hematology 2020;89:55−60highlight SPINT1 and LY9 as possible promising markers for treatment response in
CLL patients. © 2020 ISEH – Society for Hematology and Stem Cells. Published by
Elsevier Inc. All rights reserved.The natural history of chronic lymphocytic leukemia
(CLL) is highly heterogeneous. Some patients do not
require treatment for decades, while others require
direct treatment after diagnosis and experience dimin-
ished life expectancy because of CLL [1]. Since the
introduction of multiple novel treatments, there is a
growing need for informative prognostic markers with
clinical significance that can influence the choice of
standard of care [1].
To date, several prognostic markers have been iden-
tified, including immunoglobulin heavy chain variable
(IGHV) gene mutation status, ZAP70, chromosomal
alterations, CD38, CD40L, and biochemical parameters
(e.g., lactate dehydrogenase and b2-microglobulin
[b2M]) [1]. Yet, the identification of new prognostic
parameters that are able to predict clinical outcome
after treatment is important for patient management
and may be useful in guiding therapeutic decisions.
Proteomic data are increasingly being used for bio-
marker discovery and for gaining mechanistic insight
into lymphoid malignancies. Among the general popu-
lation, an immune system environment that is charac-
terized by elevated levels of B-cell stimulatory
cytokines has been suggested to contribute to the
development of B-cell lymphoma, including CLL [2
−5]. In a study including 105 newly diagnosed and
untreated CLL patients, high levels of soluble CD23
(sCD23) at the time of initial diagnosis were a strong
predictor of progressive disease within the first year of
disease presentation [6]. Other studies obtained similar
results implicating sCD23 as a suitable marker with
prognostic potential in CLL at diagnosis [7−9].
The aims of this pilot study were (1) to validate the
prognostic ability of known proteomic markers (in par-
ticular B-cell activation markers such as sCD23 and
sCD27) measured pretreatment for treatment response
in CLL patients, and (2) to search for new proteomic
markers and their biological pathways that might be
related to treatment response.Methods
Study subjects were selected from the HOVON 109 clinical
study, which is a phase I/II trial designed for efficacy and
safety of first-line therapy involving chlorambucil, rituximab,
and lenalidomide in elderly patients and young frail patients
with advanced CLL [10]. Total treatment duration was 12
months, and all patients were followed until 5 years after
registration. Of 63 patients enrolled in the HOVON 109
study, 51 with an available sample at baseline were included
in our current pilot study. Clinical data were collected from
the HOVON database.Four commercially available proteomic panels (Oncology,
Inflammation, Immune response, and Development; Olink
Bioscience, Uppsala, Sweden) including 360 low-abundance
serum proteins were selected for this study, covering multiple
proteomic markers previously associated with incidence or
progression of CLL in published clinical and population-
based studies [2−9]. Serum samples were analyzed using a
multiplex proximity extension assay. Data were expressed in
the arbitrary unit NPX (Normalized Protein eXpression) on a
log2 scale and linearized using the formula 2
NPX, where a
high NPX value corresponds to a high protein concentration
(Supplementary Table E1, online only, available at www.
exphem.org).
Statistical procedures are provided in detail in the Supple-
mentary Data (online only, available at www.exphem.org).
As the analyses of B-cell activation markers that were found
to be predictive in the general population (sCD23 and
sCD27) rely on a prior hypothesis, these were not corrected
for multiple testing. All other p values were corrected for
multiple testing.Results
Clinical characteristics of the CLL patients (30 males, 21
females; median age: 71 years) are summarized in
Supplementary Table E2 (online only, available at www.
exphem.org). Until 5 years after registration, 26 events
were recorded. We first evaluated measured levels of the
proteomic markers in the context of other known prognos-
tic factors. Mutated IGHV status was significantly associ-
ated with lower levels of sCD23 and higher levels of
nuclear factor of activated T cells 3 (NFATC3), while a
positive association between b2M levels and 58 markers
was established (Supplementary Table E3, online only,
available at www.exphem.org). No marker remained sig-
nificantly associated with Rai and cytogenetic aberrations
after multiple testing correction.
In log-rank testing of known prognostic factors, male
patients had shorter EFS as compared with female patients,
and IGHV-mutated CLL patients had longer EFS than
unmutated CLL patients (Supplementary Figure E1, online
only, available at www.exphem.org). No significant EFS
effects were seen for b2M levels, Rai stage, or well-
defined chromosome aberrations. The latter may be due to
the small number of cases with these aberrations in our
pilot study.
From the previously studied B-cell activation proteo-
mic markers (Supplementary Table E4, online only,
available at www.exphem.org), only the sCD23 level
was significantly associated with EFS (HR = 1.56, 95%
CI = 1.02−2.4, p = 0.04) in the univariate model, while
none appeared significantly correlated to EFS in the
models adjusted for gender and IGHV status. As
F. Saberi Hosnijeh et al. / Experimental Hematology 2020;89:55−60 57sCD23 level was related to IGHV status, the interaction
term was further included in the adjusted model that
resulted in a borderline significant association for
sCD23 (hazard ratio [HR] = 0.23, 95% confidence inter-
val [CI] = 0.04−1.14, p = 0.07).
When using median values as threshold, patients
with sCD23 and sCD27 levels above the median did
have a shorter EFS than those with marker levels
below the median (Figure 1A,B). Notably, when com-
bining these markers with significant CLL prognostic
factors in this cohort (i.e., IGHV mutation status and
gender), sCD23 or sCD27 levels above the median
were associated with the lowest EFS in unmutated
IGHV patients (Figure 1C,D). In contrast, survival dis-
tributions for male and female patients with sCD23 or
sCD27 levels above the median did not differ signifi-
cantly (Figure 1E,F).
Several newly studied proteomic markers were signif-
icantly associated with EFS in Cox regression models,
albeit that upon multiple testing correction, even the top
four proteomic markers from the models exhibited only
a trend toward significance (Supplementary Table E5,
online only, available at www.exphem.org). Neverthe-
less, the two markers with p values closest toFigure 1. Kaplan−Meier curves for EFS related tsignificance, that is, serine peptidase inhibitor SPINT1
and surface antigen LY9, were associated with a signifi-
cantly longer EFS in patients with marker levels equal
or lower than the median (Figure 2). Moreover, CLL
patients with higher levels of IFNLR1 had a shorter
EFS than those patients with marker levels equal to or
lower than the median.
Findings were independently validated via Lasso
regression (details are in the Supplementary Data).
The stepwise Cox regression model including gender
and IGHV mutation status plus sCD23 and the top four
proteomic markers from the univariate and/or multivar-
iable (model M2, Table 1) revealed a significant inde-
pendent effect for sCD23 (HR = 0.27, 95% CI = 0.12
−0.58, p = 0.0008), SPINT1 (HR = 3.6, 95% CI = 1.12
−11.5, p = 0.03), LY9 (HR = 7.03, 95% CI = 1.6−30.8,
p = 0.009), and CLEC7A (HR = 0.43, 95% CI = 0.27
−0.7, p = 0.0007) over gender and IGHV status. The
AUC of the model was higher (0.61) compared with
that of the model including only gender and IGHV sta-
tus (0.38). Because of the limited sample size of our
study resulting in the wide confidence intervals, these
findings should be interpreted with caution and require
validation in larger studies.o the B-cell activation proteomic markers.
Figure 2. Kaplan−Meier curves for EFS related to the top four proteomic markers in univariate and/or multivariable Cox regression analysis.
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In this pilot study, we were able to validate sCD23 lev-













R2 (correcteda) 0.28 (0.24)
AUC (correcteda) 0.40 (0.38)
AUC=Area under the curve; CI=confidence interval; NS=nonsignificant.
aR2 and AUC corrected for overfitting by 100 times bootstrapping.shorter EFS, which is consistent with previous studies
[7]. Soluble CD23 is released from activated B cells
and can itself induce further B-cell stimulation as wellknown prognostic factors
M2 (stepwise)
p HR (95% CI) p
0.04 0.21 (0.06−0.66) 0.008
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bly, sCD23 seems to be associated with IGHV status,
since mutated CLL patients had significantly lower lev-
els of sCD23, as compared with unmutated patients.
When both markers are used, patients with unmutated
IGHV genes with sCD23 levels above the median can
be regarded as very poor prognostic group. Similarly,
patients with unmutated IGHV genes and high levels
of sCD27 were found to have an even poorer progno-
sis. High sCD27 levels were described to be associated
with higher Rai stage, b2M, and LDH among CLL
patients [11,12]. Here we found that high levels of
sCD27 were associated with b2M levels and inferior
prognosis.
Our study further indicated that higher levels of
SPINT1 are associated with shorter EFS time and
higher b2M levels. SPINT1, an enzyme that is encoded
by the Kunitz-type protease inhibitor 1 gene, modulates
matriptase proteolytic activity. Matriptase was identi-
fied in Burkitt lymphoma cells [13] and later in CLL
[14]. In fact, it is highly upregulated in CLL and pro-
motes cancer cell invasion either directly by degrading
matrix proteins or indirectly by activating growth fac-
tors or through yet unknown mechanisms [14].
In our cohort, CLL patients with high LY9 levels
had an inferior EFS as compared with patients with
low LY9 levels. LY9 is known to interact with SLAM-
associated protein that has been implicated in autoim-
munity. It has been reported that LY9 is a naturally
processed antigen in CLL and can serve as tumor-asso-
ciated antigen in this disease [15]. It was reported that
LY9-specific cytotoxic T cells from CLL patients effi-
ciently recognized native and CD40L-activated autolo-
gous malignant CLL cells via MHC-I molecules. These
findings provide strong evidence that LY9 can be
employed for the design of T cell-based immunothera-
peutic strategies of LY9-expressing malignancies
including CLL [15] and, thus, underline the impact of
the results from our current study.
A major strength of this pilot study is the large set of
novel proteomic markers, which we measured and which
were previously not extensively described in CLL patients.
Despite the relatively small number of available cases,
which had an impact on statistical power, our pilot study
identified SPINT1 and LY9 as promising independent prog-
nostic proteomic markers next to sCD23 and sCD27 in
patients treated for CLL. Further studies with larger sample
sizes are required to validate these results. Also, as proteo-
mic markers were solely measured before treatment,
changes in marker levels during treatment should be evalu-
ated in new CLL patient cohorts.
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Supplementary Methods
Written informed consent was obtained before enrollment in
the trial. The study was approved by an accredited Ethical
Committee and Institutional Review Board and was per-
formed according to the Declaration of Helsinki, the Interna-
tional Conference on Harmonization Good Clinical Practice
Guidelines and the European Union Clinical Trial Directive
(2001/20/EG). The study was registered with EuraCT number
2010-022294-34 [1].Protein measurements. Serum samples were analyzed using a
multiplex proximity extension assay. In brief, 1 mL sample was
incubated in the presence of proximity antibody pairs tagged with
DNA-reporter molecules. Once the pair of antibodies is bound to
their corresponding antigens, the respective DNA tails form an
amplicon by proximity extension, which was quantified by high-
throughput real-time PCR (BioMarkTM HD System, Fluidigm
Corporation). Protein abundance directly correlates with the gener-
ated fluorescent signal, which is expressed in quantitation cycles
produced by the BioMark’s Real-Time PCR Software following
the Proseek Multiplex protocol. To minimize variation within and
between runs, data (Ct values) were normalized using both an
internal control (extension control) and an interplate control, and
then transformed using a pre-determined correction factor.
The limit of detection was determined for each biomarker
based on the mean value of 4 controls analyzed in each run.
Thirty-five markers were excluded from statistical analyses
because of a high non-detection rate in the cohort (i.e. >30%
of the cases) (Supplementary Table E1, footnote). For 35
samples, the non-detection rate ranged from 2% to 30%
(median 7%) and those were set to the value of the lower
limit of quantification divided by the square root of two.
Around 83% of markers were detected in all samples. The
list of biomarkers (n=322) included in the statistical analyses
and their median value is shown in Supplementary Table E1.Statistical analyses. Differences in marker distributions
across different levels of prognostic factors were evaluated
by Wilcoxon tests. Kaplan−Meier plot and Log-rank test
were used to examine the survival distribution for protein
markers (≤ median or >median) and other known prognostic
factors. The median of the protein markers are shown in
Supplementary Table E1.
Cox proportional hazard models were used for testing the
effects of the markers for event-free survival (EFS; time
from registration to induction failure, progression, or death
from any cause, whichever comes first). Induction failure
was defined as not having achieved at least a PR during/after
a maximum of 12 cycles. Unadjusted analyses were carried
out for each proteomic marker. Due to the limited sample
size of the study, the Cox model of proteomic markers was
further adjusted only for significant known prognostic factors
(gender and IGHV status).
Of interest was the added prognostic value of proteomic
markers that might help to assess prognosis in clinical prac-
tice. Two models, one containing only significant known
prognostic markers and the other containing the first modelplus significant proteomic markers were compared by esti-
mating the area under a ROC (receiver operating characteris-
tic) curve (AUC) for EFS. R square and AUC corrected for
overfitting by 100 bootstrapping were reported.
Validation analysis. As standard regression models perform
poorly in a situation with a data set containing a number of varia-
bles superior to the number of samples, we additionally applied
the least absolute shrinkage and selection operator (Lasso) tech-
nique for variable selection [2]. It is a powerful method that per-
form two main tasks: regularization and feature selection. In order
to do so the method applied a shrinking (regularization) process
in which the coefficients of the regression variables were penal-
ized, thus shrinking some of them to zero. During the feature
selection process the variables that still have a non-zero coeffi-
cient after the shrinking process were selected to be part of the
model. Optimal tuning parameter λ, which controls the strength of
the penalty, was obtained by 5 folds cross-validation.
Supplementary Results
Validation analysis by means of Lasso regression. In
total 8 proteomic markers were selected in association
with EFS in Lasso analysis (Supplementary Table E6).
Interestingly, five proteomic markers suggested in our
Cox regression models (LY9, SPINT1, ITM2A,
IFNLR1, and CLEC7A) were among the selected varia-
bles, thus supporting the validity of these markers as
possible prognostic markers.
Fourteen proteomic markers [sCD23, TCL1A, ITM2A,
CLEC7A, LY9, VEGFR-3, IFNLR1, SPINT1, TNF
receptor-associated factor 2 (TRAF2), Semaphorin-7A
(SEMA7A), signal-regulatory protein beta-1 (SIRPB1), C-
type lectin domain family 4 member C (CLEC4C), tripep-
tidyl peptidase 1 (TPP1), monocyte chemoattractant protein
1 (MCP1)] found to be associated with EFS in the
adjusted Cox regression models at p<0.05 and/or in Lasso
analysis were subjected to computational functional analy-
sis. Molecular functions, biological process, and cellular
components related to the proteins are shown in
Supplementary Figure E2. Due to the limited sample size
and protein numbers, further pathway analyses and statisti-
cal enrichment detection were not possible.
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Supplementary Table E1. Proteomic markers with their median values included in the statistical analyses
Marker Label M* Marker Label M* Marker Label M*
DevOID01400 CTSF 2.32 DevOID01447 CD109 2.56 DevOID01490 TPP1 4.60
DevOID01401 MATN2 2.68 DevOID01448 VSIG4 5.13 DevOID01491 CD209 4.35
DevOID01402 HTRA2 0.68 DevOID01449 CRIM1 1.71 ImmOID00936 PPP1R9B 4.17
DevOID01403 MFGE8 3.72 DevOID01450 CGA 4.77 ImmOID00937 GLB1 0.72
DevOID01405 ACAN 2.97 DevOID01451 CLEC14A 3.82 ImmOID00938 PSIP1 5.78
DevOID01406 ITGB1 6.14 DevOID01452 CA6 0.37 ImmOID00939 ZBTB16 1.60
DevOID01407 DKK3 4.23 DevOID01453 MIF 7.56 ImmOID00940 IRAK4 2.02
DevOID01408 SPINT2 2.46 DevOID01454 CRELD2 2.50 ImmOID00941 TPSAB1 3.12
DevOID01409 APP 4.16 DevOID01455 ITGA5 1.79 ImmOID00942 HCLS1 5.49
DevOID01410 HAVCR2 3.21 DevOID01456 PEAR1 5.05 ImmOID00943 CNTNAP2 1.42
DevOID01411 DSC2 4.59 DevOID01457 MESDC2 2.14 ImmOID00944 CLEC4G 2.60
DevOID01412 TMSB10 6.03 DevOID01458 CD99L2 1.59 ImmOID00945 IRF9 3.80
DevOID01413 ANGPTL4 2.43 DevOID01459 SCARF1 6.74 ImmOID00946 EDAR 1.15
DevOID01414 INHBC 1.56 DevOID01460 LGMN 3.02 ImmOID00949 CLEC4C 4.28
DevOID01415 SPINK1 3.37 DevOID01461 SEMA7A 6.72 ImmOID00950 IRAK1 1.38
DevOID01416 CLEC11A 3.69 DevOID01462 COLEC12 3.57 ImmOID00951 CLEC4A 3.63
DevOID01417 PDGFRB 3.95 DevOID01463 GUSB 3.42 ImmOID00952 PRDX1 3.06
DevOID01418 COCH 5.47 DevOID01492 FUT3/FUT5 2.44 ImmOID00953 PRDX3 -0.18
DevOID01419 FCRL5 5.72 DevOID01465 STIP1 0.64 ImmOID00954 FGF2 1.95
DevOID01420 PILRA 2.84 DevOID01466 B4GAT1 4.18 ImmOID00955 PRDX5 6.64
DevOID01421 B4GALT1 3.07 DevOID01467 CD69 5.76 ImmOID00956 DPP10 0.54
DevOID01422 CD300LG 3.38 DevOID01468 CRHBP 2.07 ImmOID00957 TRIM5 2.85
DevOID01423 PARK7 4.27 DevOID01469 MSMB 2.64 ImmOID00958 DCTN1 5.06
DevOID01424 BLVRB 0.11 DevOID01470 SPINT1 1.59 ImmOID00960 CDSN 3.07
DevOID01426 CD74 2.69 DevOID01471 FSTL3 2.23 ImmOID00961 GALNT3 1.73
DevOID01427 CCL21 0.58 DevOID01472 IL13RA1 1.65 ImmOID00963 TRAF2 2.27
DevOID01428 PTPRF 2.72 DevOID01473 CD58 2.26 ImmOID00964 TRIM21 1.94
DevOID01429 BCAM 3.36 DevOID01474 SCGB3A1 2.34 ImmOID00965 LILRB4 3.26
DevOID01430 SIRPB1 3.17 DevOID01475 NOV 3.26 ImmOID00967 KRT19 3.10
DevOID01431 IGF2R 6.25 DevOID01476 CNTN4 3.52 ImmOID00968 ITM2A 1.16
DevOID01432 P4HB 0.28 DevOID01477 CA2 3.85 ImmOID00969 HNMT 0.64
DevOID01433 FUCA1 5.83 DevOID01478 XG 4.00 ImmOID00971 MILR1 2.44
DevOID01434 ESAM 3.21 DevOID01479 ARSA 2.93 ImmOID00972 EGLN1 4.24
DevOID01436 BST1 1.28 DevOID01480 PPIB 3.93 ImmOID00973 NFATC3 -0.07
DevOID01437 CST6 4.85 DevOID01481 SPINK5 0.04 ImmOID00974 LY75 3.11
DevOID01438 MYOC 3.19 DevOID01482 OMD 2.08 ImmOID00976 EIF4G1 5.16
DevOID01439 SNAP29 4.92 DevOID01483 PEBP1 5.74 ImmOID00977 CD28 1.13
DevOID01440 WFIKKN2 3.37 DevOID01484 PAMR1 3.78 ImmOID00978 PTH1R 1.47
DevOID01441 CDON 2.20 DevOID01485 ROBO1 2.08 ImmOID00979 BIRC2 0.53
DevOID01442 CD177 4.79 DevOID01486 CD23 11.3 ImmOID00980 HSD11B1 2.36
DevOID01443 NID2 1.27 DevOID01487 LAMA4 2.45 ImmOID00982 PLXNA4 3.31
DevOID01444 DAG1 2.75 DevOID01488 LAIR1 4.55 ImmOID00983 SH2B3 1.54
DevOID01445 CD97 5.71 DevOID01489 RELT 5.37 ImmOID00984 FCRL3 2.70
ImmOID00985 CKAP4 6.32 InfOID00483 IL-17C 0.99 InfOID00542 CD40 10.9
ImmOID00987 HEXIM1 4.31 InfOID00484 MCP-1 11.0 InfOID00545 FGF-19 8.29
ImmOID00988 CLEC4D 2.29 InfOID00486 CXCL11 8.67 InfOID00549 MCP-2 8.03
ImmOID00989 PRKCQ 0.27 InfOID00487 AXIN1 3.49 InfOID00550 CASP-8 4.73
ImmOID00990 MGMT 4.26 InfOID00490 CXCL9 9.31 InfOID00551 CCL25 6.09
ImmOID00991 TREM1 2.03 InfOID00491 CST5 5.89 InfOID00552 CX3CL1 5.63
ImmOID00992 CXADR 1.55 InfOID00494 OSM 5.38 InfOID00553 TNFRSF9 10.9
ImmOID00994 SRPK2 1.18 InfOID00496 CXCL1 8.40 InfOID00554 NT-3 1.14
ImmOID00995 KLRD1 5.69 InfOID00498 CCL4 8.93 InfOID00555 TWEAK 9.20
ImmOID00996 BACH1 1.84 InfOID00499 CD6 6.90 InfOID00556 CCL20 3.66
ImmOID00997 PIK3AP1 5.43 InfOID00501 IL18 8.73 InfOID00557 ST1A1 4.49
ImmOID00999 STC1 5.25 InfOID00502 SLAMF1 2.04 InfOID00558 STAMPB 4.77
ImmOID01001 FAM3B 4.04 InfOID00504 MCP-4 3.92 InfOID00560 ADA 3.74
ImmOID01002 SH2D1A 1.39 InfOID00505 CCL11 7.63 InfOID00561 TNFB 6.53
ImmOID01003 ICA1 1.44 InfOID00506 TNFSF14 7.08 InfOID00562 CSF-1 7.96
ImmOID01004 DFFA 5.64 InfOID00507 FGF-23 1.13 OncOID00655 TXLNA 6.14
ImmOID01005 DCBLD2 2.35 InfOID00508 IL-10RA 0.87 OncOID00657 CPE 3.82
ImmOID01006 FCRL6 2.07 InfOID00509 FGF-5 0.64 OncOID00658 KLK13 3.15
(continued )
60.e2 F. Saberi Hosnijeh et al. / Experimental Hematology 2020;89:55−60
Supplementary Table E1 (Continued)
Marker Label M* Marker Label M* Marker Label M*
ImmOID01007 NCR1 1.82 InfOID00510 MMP-1 13.6 OncOID00659 CEACAM1 6.66
ImmOID01010 IFNLR1 3.52 InfOID00511 LIF-R 2.60 OncOID00660 MSLN 4.01
ImmOID01011 DAPP1 1.30 InfOID00512 FGF-21 4.58 OncOID00661 TNFSF13 7.59
ImmOID01013 SIT1 3.79 InfOID00513 CCL19 8.59 OncOID00662 EGF 11.1
ImmOID01014 MASP1 1.08 InfOID00514 IL-15RA 0.56 OncOID00663 TNFRSF6B 6.60
ImmOID01015 LAMP3 3.72 InfOID00515 IL-10RB 7.30 OncOID00664 SYND1 6.92
ImmOID01016 CLEC7A 3.36 InfOID00517 IL-18R1 6.84 OncOID00665 TGFR-2 6.71
ImmOID01017 CLEC6A 2.38 InfOID00518 PD-L1 4.50 OncOID00666 IL6 3.83
ImmOID01018 DDX58 4.17 InfOID00519 Beta-NGF 1.53 OncOID00667 CD48 7.85
ImmOID01019 IL12RB1 2.32 InfOID00520 CXCL5 9.74 OncOID00668 SCAMP3 6.67
ImmOID01020 TANK 2.48 InfOID00521 TRANCE 3.97 OncOID00669 LY9 8.22
ImmOID01021 ITGA11 1.35 InfOID00522 HGF 8.63 OncOID00670 IFN-gamma-R1 5.34
ImmOID01023 LAG3 2.53 InfOID00523 IL-12B 4.65 OncOID00671 ITGAV 3.60
ImmOID01025 CD83 3.56 InfOID00527 MMP-10 5.44 OncOID00672 TRAIL 8.07
ImmOID01026 ITGB6 1.63 InfOID00528 IL10 3.27 OncOID00673 hK11 6.72
ImmOID01027 BTN3A2 1.98 InfOID00530 CCL23 9.95 OncOID00674 GPC1 5.05
InfOID00471 IL8 10.9 InfOID00531 CD5 8.18 OncOID00675 TFPI-2 8.10
InfOID00472 VEGFA 9.92 InfOID00532 CCL3 7.86 OncOID00676 hK8 7.29
InfOID00474 MCP-3 3.08 InfOID00533 Flt3L 9.08 OncOID00677 VEGFR-2 7.14
InfOID00475 GDNF 0.90 InfOID00534 CXCL6 8.46 OncOID00678 LYPD3 4.70
InfOID00476 CDCP1 3.33 InfOID00535 CXCL10 8.78 OncOID00679 PODXL 3.60
InfOID00477 CD244 5.69 InfOID00536 4E-BP1 7.53 OncOID00680 S100A4 3.26
InfOID00478 IL7 2.53 InfOID00538 SIRT2 3.35 OncOID00681 IGF1R 3.52
InfOID00479 OPG 10.6 InfOID00539 CCL28 0.94 OncOID00682 ERBB2 7.79
InfOID00480 LAP TGF-b-1 8.00 InfOID01213 DNER 7.36 OncOID00683 ERBB3 8.08
InfOID00481 uPA 10.2 InfOID00541 EN-RAGE 6.03 OncOID00684 SCF 9.28
OncOID00685 SPARC 6.06 OncOID00708 50-NT 10.8 OncOID00730 CD207 2.81
OncOID00686 GZMH 5.97 OncOID00709 CDKN1A 2.46 OncOID00731 ICOSLG 6.45
OncOID00687 TGF-alpha 8.85 OncOID00710 DLL1 10.4 OncOID00732 WFDC2 8.68
OncOID00688 FURIN 9.21 OncOID00711 MK 5.92 OncOID00733 CXCL13 9.70
OncOID00689 CYR61 5.38 OncOID00712 ABL1 4.42 OncOID00734 MAD homolog 5 3.62
OncOID00690 hK14 6.94 OncOID00713 FGF-BP1 5.19 OncOID00735 ADAM-TS 15 1.56
OncOID00691 FADD 2.65 OncOID00714 TLR3 5.51 OncOID00736 CD70 6.96
OncOID00692 MetAP 2 5.38 OncOID00715 LYN 3.57 OncOID00737 RSPO3 3.45
OncOID00693 PVRL4 4.83 OncOID00716 RET 5.30 OncOID00738 FR-gamma 6.53
OncOID00694 FASLG 9.28 OncOID00717 VIM 6.17 OncOID00739 CEACAM5 1.24
OncOID00695 EPHA2 3.93 OncOID00718 TNFRSF19 4.59 OncOID00740 VEGFR-3 7.22
OncOID00696 ITGB5 7.09 OncOID00719 CRNN 4.47 OncOID00741 MUC-16 4.50
OncOID00697 Gal-1 7.07 OncOID00720 TCL1A 11.2 OncOID00742 WIF-1 4.94
OncOID00698 SEZ6L 3.48 OncOID00721 CD160 6.24 OncOID00743 GZMB 4.44
OncOID00749 GPNMB 6.85 OncOID00722 TNFRSF4 5.77 OncOID00744 FCRLB 1.42
OncOID00700 CAIX 4.02 OncOID00723 MIC-A/B 4.63 OncOID00745 ANXA1 4.90
OncOID00701 MIA 10.2 OncOID00724 WISP-1 6.27 OncOID00746 FR-alpha 6.72
OncOID00702 CTSV 3.44 OncOID00725 CXL17 3.91
OncOID00703 CD27 11.0 OncOID00726 PPY 9.42
OncOID00704 XPNPEP2 8.56 OncOID00727 S100A11 4.34
OncOID00705 ERBB4 5.26 OncOID00728 AREG 3.40
OncOID00707 ADAM 8 6.27 OncOID00729 ESM-1 8.58
*Median (M) normalized protein expression level on log2 scale; The excluded markers due to a high non-detection rate were NFASC, KPNA1,
BDNF, IL-1 alpha, IL-2, IL-4, IL-5, IL-13, IL-20, IL-24, IL-33, TSLP, EIF5A, IL-22 RA1, ARTN, PLA2G4A, IL-20RA, IFN-gamma, SPRY2,
ARNT, IL-2RB, NTF4, PADI2, TNF, LIF, NRTN, JUN, DGKZ, FXYD5, NF2, IL-17A, PTPN6, ITGA6, NUDT5, CXCL12.
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Supplementary Table E2. Characteristics of the study participants
N=51






















Survival duration* 31.7 (15.8-62.1)
Progression free survival (PFS) status 27
No progression 27
Progression 24
PFS duration* 24.4 (1.25-60.9)
Event free survival (EFS) status
No event 25
Event 26
EFS duration* 23 (1.25-60.9)
*Median (range); Missing numbers: Del17p13 (n=2), Immunoglob-
ulin heavy chain variable genes (IGHV) mutation status (n=4), b2M
(n=10)
Supplementary Table E3. Proteomic markers significantly associated with well-known CLL
Sex IGHV Mut. b2M b2M (cont.) b2M (cont.)
ANGPTL4 CD23 TNFRSF4 TNFRSF6B FSTL3














*inverse association; Beta 2-Microglobulin (b2M); lactate dehydrogenase
Supplementary Table E4. Cox models for EFS related to individual B-cell activa-
tion proteomic markers found to be predictive in population-based studies
Markers Univariate Multivariable*
HR (95% CI) P HR (95% CI) P
CD23 1.56 (1.02-2.4) 0.04 1.21 (0.80-1.86) 0.37
CD27 2.9 (0.71-11.9) 0.14 2.45 (0.53-11.4) 0.25
*Each protein marker individually adjusted for gender and IGHV
mutation status; There was a significant interaction effect between
sCD23 and IGHV status (HR=2.75, 95% CI= 1.04-7.27, P=0.04)
implying that the effect of sCD23 on EFS would be different
between mutated and unmutated patients (HR of 0.23 for one unit
increase in sCD23 in mutated male CLL patients vs. HR of 3.4 for
unmutated male CLL patients).
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b2M (cont.) LDH pblymph Pblymph (cont.)
LILRB4 BCAM PSIP1 HEXIM1
CD28 ITGB1 DFFA DDX58
-R1 BCAM TFPI-2 ABL1 IFNLR1
CD5 FSTL3 SIT1 MASP1
CSF-1 FGF-23 SRPK2 LY75
MIC-A/B EPHA2 PPP1R9B PEBP1
FCRL6 ROBO1 CCL28 NT-3
CD244 HTRA2 TMSB10 HCLS1
IL18 SCF* IRF9 IRAK1




(LDH); peripheral B lymphocyte number (pblymph)
Supplementary Table E5. Top 4 proteomic markers from the univariate and multi-
variable Cox regression models for EFS
Markers Univariate
HR (95% CI) P
SPINT1 3.16 (1.64-6.05) 0.0005
LY9 5.1 (1.94-13.41) 0.0009
IFNLR1 2.85 (1.51-5.40) 0.0013
ITM2A 3.40 (1.61-7.12) 0.0013
Multivariable*
TCL1A 0.70 (0.12-0.86) 0.0020
ITM2A 2.81 (1.29-6.13) 0.0095
CLEC7A 0.60 (0.40-0.90) 0.0145
LY9 3.10 (1.25-7.68) 0.0147
*Each protein marker individually adjusted for gender and IGHV
mutation status; Bonferroni correction level: p=0.05/322=0.0002














The lambda.min refers to value of λ at the lowest cross-validation
error.
Supplementary Figure E1. Kaplan-Meier curves for EFS related to well-known CLL prognostic factors
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Supplementary Figure E2. Molecular functions, biological process, and cellular components related to 14 proteins (with P<0.05 in adjusted
Cox model and/or Lasso model) using the Protein Analysis Through Evolutionary Relationships (PANTHER) classification system
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